MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: Complete remission after treatment with rituximab

Lupus

Volumn 19, Issue 10, 2010, Pages 1243-1245

  Tektonidou, M G ^a  

^a Athens Euroclinic   (Greece)

Author keywords

lymphoma of lacrimal glands; MALT lymphoma; rituximab; systemic lupus erythematosus

Indexed keywords

CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CONTRAST ENHANCEMENT; EYELID SWELLING; FEMALE; HUMAN; LACRIMAL GLAND TUMOR; LUPUS ERYTHEMATOSUS NEPHRITIS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SWELLING; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TUMOR BIOPSY;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; EYE NEOPLASMS; FEMALE; HUMANS; LACRIMAL APPARATUS DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, B-CELL, MARGINAL ZONE; MAGNETIC RESONANCE IMAGING; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 77956241018     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310367659     Document Type: Article

References (13)

1. Hainsworth JD, Litchy S., Burris III HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002 ; 20: 4261-4267.
2. Ghielmini M. Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example. Hematology Am Soc Hematol Educ Program 2005 ; 321-328.
3. Ramos-Casals M., Soto MJ, Cuadrado MJ, Khamashta MA Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009 ; 18: 767-776.
4. Lee JL, Kim MK, Lee KH, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol 2005 ; 84: 13-18.
5. Hansen A., Lipsky PE, Dörner T. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol 2007 ; 3: 561-569.
6. Voulgarelis M., Skopouli FN Clinical, immunologic, and molecular factors predicting lymphoma development in Sjögren's syndrome patients. Clin Rev Allergy Immunol 2007 ; 32: 265-274.
7. Martin DN, Mikhail IS, Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 2009 ; 50: 541-550.
8. Tonami H., Matoba M., Yokota H., Higashi K., Yamamoto I., Sugai S. Mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: initial and follow-up imaging features. AJR Am J Roentgenol 2002 ; 179: 485-489.
9. Cassidy DT, McKelvie P., Harris GJ, Rose GE, McNab AA Lacrimal gland orbital lobe cysts associated with MALT lymphoma and primary Sjögren's syndrome. Orbit 2005 ; 24: 257-263.
10. Kíratlí H., Söylemezoǧlu F., Bilgiç S., Ruacan S. Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland. Ophthal Plast Reconstr Surg 1999 ; 15: 272.
11. Lin YC, Kau HC, Kao SC, Hsu WM, Tsai CC Systemically disseminated extranodal marginal zone B-cell lymphoma of lacrimal gland in a patient with systemic lupus erythematosus. Ophthal Plast Reconstr Surg 2007 ; 23: 72-73.
12. Heinz C., Merz H., Nieschalk M., Mueller-Miny H., Koch P., Heiligenhaus A. Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland. Br J Ophthalmol 2007 ; 91: 1563-1564.
13. Pijpe J., van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005 ; 52: 2740-2750.